For Investors
From Clinical Validation to Scalable Tissue-Matching Software
First human surgery completed, a peer-reviewed method published, and a clear path from tissue banking to SaaS.
The opportunity
A Scalable Product for a Real Clinical Bottleneck
About 30% of people over 55 have some knee cartilage damage. Donor cartilage can repair large defects, but matching donor and patient is still manual, so only about 10,000 transplants happen worldwide each year, against a need roughly 25 times larger.
Our AI identifies donor tissue that fits each patient from MR images and can split one donation into several matched grafts, allowing the same tissue supply to serve two to three times as many patients.
Market
The Market Opportunity in Numbers
About 2.5 million knee replacements are performed worldwide each year, 1 million of them in the EU. Experts estimate that around 10% of these patients could be treated with cartilage transplantation instead.
Business model
From Tissue Banking
to
Software as a Service
We start by supplying matched grafts ourselves, then license the matching software to tissue banks and transplant centres once it is certified.
- Phase 1, tissue banking: we harvest, match and supply grafts.
- Phase 2, SaaS: after MDR certification, tissue banks and hospitals license our matching software.
- Phase 3, marketplace: a network for optimally matched knee cartilage across Europe and beyond.
Traction
Proof Points on
Our
Path to Market
CLINICAL
First Human Surgery
SCIENCE
Peer-Reviewed Paper
RECOGNITION
Future Unicorn Nominee
REGULATORY
MDR Pathway
PRESS
In the Media
Why GenuForm AI
An Edge That Is Hard to Copy
Clinical Pedigree
Developed with Prof. Hangody, inventor of mosaicplasty, with direct access to surgeons.
More Grafts per Donor
One donation can serve two to three recipients, helping make better use of a scarce supply.
The Team
Medicine, Mathematics
and
AI in One Team
Dr. Gyorgy Hangody
Surgeon
10+ yr surgery
Cartilage repair expert
Angel Investors
Momentum
What’s Been
Happening
in 2026
Future Unicorn Award
- Nominated by IVSZ
- Representing Hungarian medtech in Europe
International Stage
- health.tech global summit, Basel
- London Tech Week, with XPAND
- Hello Tomorrow, Amsterdam
- Singapore AI Week
Growing Team
- Two new AI and software engineers
- Growth on the AI and interface side
Investment
Interested in the Next
Investment Round?
We can walk investors through the clinical results, regulatory roadmap and business model. Request the deck or arrange a call with the founders.
FAQ
Questions Investors
Ask Us
What stage is the company at?
Moving from clinical validation to commercial launch: first surgery done, method published, tissue bank and MDR certification under way.
How will the company make money?
First by supplying matched grafts to hospitals, then, after MDR certification, through SaaS licences for tissue banks and transplant centres.
Which markets come first?
The UK and Germany, the two largest opt-in donor markets, where demand for donor tissue exceeds local supply. The rest of Europe follows, and MDSAP opens the US, Canada.
What are the alternatives today?
Knee replacement, which limits flexion and often needs revision after 15–20 years, and cell-based repair, which is costly and suits only shallow lesions.
What will new funding be used for?
Building the tissue bank infrastructure and completing MDR certification.
How can I learn more?
Use the form below to request the investor deck or a call with the founders.
Get in Touch
Request the Investor Deck or
Arrange a Founder Call
Leave your name and email, and our team will get back to you.